Inhibition of VISTA leads to increased infiltration and activation of CD8 + T cells and re-programmes macrophages towards an immune-stimulatory phenotype, representing a promising therapeutic strategy for enhancing anti-tumour immune response in patients with TNBC. This evidence concerns the gene CD8A and neoplasm.